Coronary Artery DiseaseASAN MVNCT02039752
Asan Multivessel Registry
An observational study of Coronary Artery Disease, run by Seung-Jung Park at 1 site in South Korea.
Trial summary
The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Treatment
- How many people
- 25,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- Mar 2014to Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with multivessel disease from 1995 in Asan Medical Center
Who may be able to join
- Patients with multivessel disease from 1995 in Asan Medical Center
- Age 19 and more
Who cannot join
- For prospective cohort, not agreeing to participate with written informed consent form
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Asan Medical Center
Seoul
Seung-Jung Park, MD,PhD, sjpark@amc.seoul.kr
Jung-Hee Ham, cvcrc5@amc.seoul.kr
About this study
Official title: Asan Medical Center Registry for Multivessel
The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.
- Conditions
- Coronary Artery Disease
- Being tested
- Treatment
- Keywords
- Multivessel
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TreatmentOther
Also called Medically, Surgically, Percutaneously
| Study group | Role | What they receive |
|---|---|---|
| Multivessel | from 1995 Receives: Other: Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
composite event
death, myocardial infarction, stroke, revascularization
Measured: 1year
Secondary outcomes (8)
Death
Measured: 1year
Myocardial Infarction
Measured: 1year
Stroke
Measured: 1year
Revascularization
Measured: 1year
Angina symptom
Measured: 1year
Bleeding
Measured: 1year
Re-hospitalization
Measured: 1year
Stent thrombosis
by ARC(Academic Research Consortium) category
Measured: 1year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2014 (estimated)
- Study startMar 2014
- Primary completionJun 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 25,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seung-Jung Park
- Sponsor type
- University, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Responsible party
- Sponsor-investigator, Seung-Jung Park, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02039752
- Sponsor's protocol ID
- AMCCV2013-15
- Acronym
- ASAN MV
- Status last verified
- Dec 2025
- First submitted
- 14 Jan 2014
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Park J, Kim SH, Kim M, Lee J, Choi Y, Kim H, Kim TO, Kang DY, Ahn JM, Yoo JS, Kim HJ, Kim JB, Choo SJ, Chung CH, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Impact of Optimal Medical Therapy on Long-Term Outcomes After Myocardial Revascularization for Multivessel Coronary Disease. Am J Cardiol. 2023 Sep 15;203:81-91. doi: 10.1016/j.amjcard.2023.06.083. Epub 2023 Jul 21.
PubMed 37481816Kim TO, Kang DY, Ahn JM, Kim SO, Lee PH, Lee J, Kim JH, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan Medical Center-Multivessel Revascularization Registry Investigators. Prognostic Impact of Mildly Impaired Renal Function in Patients Undergoing Multivessel Coronary Revascularization. J Am Coll Cardiol. 2022 Apr 5;79(13):1270-1284. doi: 10.1016/j.jacc.2022.01.035.
PubMed 35361350Kim TO, Ahn JM, Kang DY, Park H, Kim SO, Lee PH, Lee J, Kim JH, Jeong YJ, Yang Y, Hyun J, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Long-Term Outcomes After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents or Coronary Artery Bypass Grafting for Multivessel Coronary Disease. Am J Cardiol. 2021 Dec 1;160:21-30. doi: 10.1016/j.amjcard.2021.08.047. Epub 2021 Oct 3.
PubMed 34610874
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Asan Medical Center Registry for Multivessel
- ClinicalTrials.gov ID
- NCT02039752
- Acronym / sponsor ID
- ASAN MV / AMCCV2013-15
- Conditions
- Coronary Artery Disease
- Keywords
- Multivessel
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 25,000 participants (estimated)
- Lead sponsor
- Seung-Jung ParkUniversity, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Study start
- Mar 2014 (actual)
- Primary completion
- Jun 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 20 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multivessel | – | Other: Treatmentfrom 1995 |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with multivessel disease from 1995 in Asan Medical Center
Key inclusion criteria (2 listed)
- Patients with multivessel disease from 1995 in Asan Medical Center
- Age 19 and more
Key exclusion criteria (1 listed)
- For prospective cohort, not agreeing to participate with written informed consent form
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TreatmentAlso: Medically, Surgically, Percutaneously | Other | Multivessel |
Primary outcome
composite event
Time frame: 1year
death, myocardial infarction, stroke, revascularization
8 secondary outcomes
Death
Time frame: 1year
Myocardial Infarction
Time frame: 1year
Stroke
Time frame: 1year
Revascularization
Time frame: 1year
Angina symptom
Time frame: 1year
Bleeding
Time frame: 1year
Re-hospitalization
Time frame: 1year
Stent thrombosis
Time frame: 1year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Derived from this study: PubMed 37481816Park J, Kim SH, Kim M, Lee J, Choi Y, Kim H, Kim TO, Kang DY, Ahn JM, Yoo JS, Kim HJ, Kim JB, Choo SJ, Chung CH, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Impact of Optimal Medical Therapy on Long-Term Outcomes After Myocardial Revascularization for Multivessel Coronary Disease. Am J Cardiol. 2023 Sep 15;203:81-91. doi: 10.1016/j.amjcard.2023.06.083. Epub 2023 Jul 21.
- Derived from this study: PubMed 35361350Kim TO, Kang DY, Ahn JM, Kim SO, Lee PH, Lee J, Kim JH, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan Medical Center-Multivessel Revascularization Registry Investigators. Prognostic Impact of Mildly Impaired Renal Function in Patients Undergoing Multivessel Coronary Revascularization. J Am Coll Cardiol. 2022 Apr 5;79(13):1270-1284. doi: 10.1016/j.jacc.2022.01.035.
- Derived from this study: PubMed 34610874Kim TO, Ahn JM, Kang DY, Park H, Kim SO, Lee PH, Lee J, Kim JH, Jeong YJ, Yang Y, Hyun J, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Long-Term Outcomes After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents or Coronary Artery Bypass Grafting for Multivessel Coronary Disease. Am J Cardiol. 2021 Dec 1;160:21-30. doi: 10.1016/j.amjcard.2021.08.047. Epub 2021 Oct 3.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Active, not recruitingPhase 4
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Coronary Artery Disease
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Not yet recruiting
Effect of Propionic Acid Supplementation on Endothelial Function
Cardiovascular Diseases, Endothelial Dysfunction
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Seung-Jung Park at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
composite event (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02039752, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026; AzTrials last refreshed its copy on 1 Nov 2026.